Loading news...
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP - Get Free Report) passed below its fifty day moving average during trading on Monday. The stock has a fifty day moving average of $81.82 and traded as low as $81.11. ANI Pharmaceuticals shares last traded at $81.33, with a volume of 774,567 shares traded. Wall Street Analysts Forecast Growth
Here is how ANI Pharmaceuticals (ANIP) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.
ANI Pharmaceuticals' rare disease growth, led by surging Cortrophin Gel sales, is outpacing Teva's slower sales momentum in this head-to-head stock comparison.
ANI Pharmaceuticals jumps 7% as 2026 guidance tops expectations, with strong sales and EPS growth fueled by momentum in the rare disease franchise.
ANI Pharmaceuticals, Inc. (ANIP) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
ANI Pharmaceuticals delivered robust 2025 results and issued bullish 2026 guidance, targeting $1.055–$1.115 billion in revenues, up 60% year-over-year. Purified Cortrophin Gel remains the primary growth engine, projected to reach $540–$575 million in 2026, supported by a 90-person commercial expansion and a pivotal Phase 4 trial. ANIP's valuation is compelling at 11.2x forward P/E, a 43% sector discount, with strong liquidity ($285 million cash) and no cash burn anticipated.
ANI (ANIP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
For full year 2025, total net revenues, adjusted non-GAAP EBITDA, and adjusted non-GAAP diluted EPS expected to be within or above guidance ranges of $854 million to $873 million, $221 million to $228 million and $7.37 to $7.64, respectively Rare Disease business delivered exceptional growth with full year 2025 Purified Cortrophin® Gel net revenues of $347.8 million, up 76% year-over-year, and ILUVIEN and YUTIQ net revenues of $74.9 million, based on preliminary, unaudited results Provides full year 2026 financial guidance, which includes: Total net revenues of $1,055 million to $1,115 million Cortrophin Gel net revenues of $540 million to $575 million Adjusted non-GAAP EBITDA of $275 million to $290 million Rare Disease business to represent approximately 60% of total net revenues Announces ~90-person expansion of Rare Disease organization to capture unique opportunity for Cortrophin Gel in acute gouty arthritis flares; expected to deploy in mid-2026 PRINCETON, N.J., Jan. 12, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced preliminary select financial results for full year 2025, provided full year 2026 financial guidance, and outlined its strategic priorities for continued growth.
PRINCETON, N.J., Jan. 06, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 3:00 p.m. PT / 6:00 p.m. ET.
ANI Pharmaceuticals' shares are up 21% in six months as strong 2025 results, repeated earnings beats and higher guidance highlight momentum in rare diseases.
ANIP's rare disease push, led by Cortrophin Gel, drove 70% sales growth in the first nine months of 2025, lifting revenue outlook.
Voya Investment Management LLC lowered its stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) by 54.3% during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,807 shares of the specialty pharmaceutical company's stock after selling 8,089
Here is how ANI Pharmaceuticals (ANIP) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.
Oregon-based Stonepine Capital Management sold all 38,597 shares of its ANI Pharmaceuticals shares in the third quarter. The shares were worth about $2.52 million.
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP - Get Free Report)'s stock price was down 3.6% on Monday after an insider sold shares in the company. The company traded as low as $79.36 and last traded at $79.8450. Approximately 86,438 shares changed hands during trading, a decline of 77% from the average daily volume of 377,608 shares. The
ANI (ANIP) could produce exceptional returns because of its solid growth attributes.
EyePoint, ANI Pharmaceuticals and Tango Therapeutics put up a stellar show in 2025 and are set to carry the momentum in 2026 as well.
Arcutis, Amicus and ANI have been highlighted in this Industry Outlook article.
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position ARQT, FOLD, ANIP, TNGX and PCRX in this volatile sector.
Here is how ANI Pharmaceuticals (ANIP) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.